Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participan...
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
Public Library of Science
2010
|
| _version_ | 1826291983073673216 |
|---|---|
| author | Lusingu, J Olotu, A Leach, A Lievens, M Vekemans, J Olivier, A Benns, S Olomi, R Msham, S Lang, T Gould, J Hallez, K Guerra, Y Njuguna, P Awuondo, K Malabeja, A Abdul, O Gesase, S Dekker, D Malle, L Ismael, S Mturi, N Drakeley, C Savarese, B Villafana, T Ballou, W Cohen, J Riley, E Lemnge, M Marsh, K Bejon, P von Seidlein, L |
| author_facet | Lusingu, J Olotu, A Leach, A Lievens, M Vekemans, J Olivier, A Benns, S Olomi, R Msham, S Lang, T Gould, J Hallez, K Guerra, Y Njuguna, P Awuondo, K Malabeja, A Abdul, O Gesase, S Dekker, D Malle, L Ismael, S Mturi, N Drakeley, C Savarese, B Villafana, T Ballou, W Cohen, J Riley, E Lemnge, M Marsh, K Bejon, P von Seidlein, L |
| author_sort | Lusingu, J |
| collection | OXFORD |
| description | The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total of 894 children received RTS,S/AS01(E) or rabies vaccine between March and August 2007. Overall, children vaccinated with RTS,S/AS01(E) had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01(E) recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were reported in 78% of subjects in the RTS,S/AS01(E) group and 74% of subjects in the rabies vaccine group. In both vaccine groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently observed solicited AE and was recorded after 11% of RTS,S/AS01(E) doses compared to 31% of doses of rabies vaccine. The candidate vaccine RTS,S/AS01(E) showed an acceptable safety profile in children living in a malaria-endemic area in East Africa. More data on the safety of RTS,S/AS01(E) will become available from the Phase 3 programme. |
| first_indexed | 2024-03-07T03:07:42Z |
| format | Journal article |
| id | oxford-uuid:b31d1130-bbca-44f6-ab89-85a8ca4a6536 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:07:42Z |
| publishDate | 2010 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:b31d1130-bbca-44f6-ab89-85a8ca4a65362022-03-27T04:16:47ZSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b31d1130-bbca-44f6-ab89-85a8ca4a6536EnglishSymplectic Elements at OxfordPublic Library of Science2010Lusingu, JOlotu, ALeach, ALievens, MVekemans, JOlivier, ABenns, SOlomi, RMsham, SLang, TGould, JHallez, KGuerra, YNjuguna, PAwuondo, KMalabeja, AAbdul, OGesase, SDekker, DMalle, LIsmael, SMturi, NDrakeley, CSavarese, BVillafana, TBallou, WCohen, JRiley, ELemnge, MMarsh, KBejon, Pvon Seidlein, LThe malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total of 894 children received RTS,S/AS01(E) or rabies vaccine between March and August 2007. Overall, children vaccinated with RTS,S/AS01(E) had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01(E) recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were reported in 78% of subjects in the RTS,S/AS01(E) group and 74% of subjects in the rabies vaccine group. In both vaccine groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently observed solicited AE and was recorded after 11% of RTS,S/AS01(E) doses compared to 31% of doses of rabies vaccine. The candidate vaccine RTS,S/AS01(E) showed an acceptable safety profile in children living in a malaria-endemic area in East Africa. More data on the safety of RTS,S/AS01(E) will become available from the Phase 3 programme. |
| spellingShingle | Lusingu, J Olotu, A Leach, A Lievens, M Vekemans, J Olivier, A Benns, S Olomi, R Msham, S Lang, T Gould, J Hallez, K Guerra, Y Njuguna, P Awuondo, K Malabeja, A Abdul, O Gesase, S Dekker, D Malle, L Ismael, S Mturi, N Drakeley, C Savarese, B Villafana, T Ballou, W Cohen, J Riley, E Lemnge, M Marsh, K Bejon, P von Seidlein, L Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title | Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title_full | Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title_fullStr | Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title_full_unstemmed | Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title_short | Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. |
| title_sort | safety of the malaria vaccine candidate rts s as01e in 5 to 17 month old kenyan and tanzanian children |
| work_keys_str_mv | AT lusinguj safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT olotua safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT leacha safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT lievensm safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT vekemansj safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT oliviera safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT bennss safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT olomir safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT mshams safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT langt safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT gouldj safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT hallezk safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT guerray safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT njugunap safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT awuondok safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT malabejaa safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT abdulo safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT gesases safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT dekkerd safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT mallel safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT ismaels safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT mturin safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT drakeleyc safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT savareseb safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT villafanat safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT ballouw safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT cohenj safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT rileye safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT lemngem safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT marshk safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT bejonp safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren AT vonseidleinl safetyofthemalariavaccinecandidatertssas01ein5to17montholdkenyanandtanzanianchildren |